Nona Biosciences Ink Pact with AstraZeneca For Monoclonal Antibody

Nona Biosciences, a worldwide biotechnology firm that offers a complete solution from “Idea to IND” (I to ITM), going from target approval and neutralizer disclosure through preclinical exploration, reported that it has gone into a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be utilized to make designated treatments in oncology.

As per the terms of the agreement, Nona Biosciences will receive US$ 19 million in accordance with the transaction. Nona is qualified to get an extra USD 10 million in potential close term achievement installments and up to USD 575 million after accomplishing determined improvement, administrative, and business achievements, as well as layered royalty payments on net deals. Moreover, Nona is qualified to get installments for the choice projects should AstraZeneca practice these choices.

“We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumour targeted therapies, to maximize the potential of our novel antibodies,” said Jingsong Wang, M.D., Ph.D., chairman of Nona Biosciences. “This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients.”

Puja Sapra, senior vice president, tumour targeted delivery, oncology R&D, AstraZeneca, said: “The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona’s innovative biologics discovery engine into novel tumour targeted therapies using AstraZeneca’s industry-leading capabilities.”

A global biotechnology company dedicated to cutting-edge technology innovation, Nona Biosciences offers a complete solution from "Idea to IND" (I to ITM), including target validation and antibody discovery through preclinical research.

Nona Biosciences, a global biotechnology company dedicated to cutting-edge technology innovation, offers a complete solution from "Idea to IND" (I to ITM), including target validation and antibody discovery through preclinical research.